Cell and Gene Therapy Collaborative News & Announcements

Enhance your impact in the health care field with crucial legal insights that intersect with health policy, innovation, and technology.

CHOP’s new translational neuroscience center, BRIDGE, works to understand basic and translational mechanisms of neurodevelopmental disorders.

The CGTC helps to accelerate clinical trials, training, and research, enabling CHOP to remain a global leader in the space.

In this week’s news, our researchers have developed the first-of-its-kind bone marrow atlas and innovative, painless wound dressings. Read on to learn more.

Evan Weber, PhD, and a research team from CHOP and Stanford Medicine discovered that the protein FOXO1 plays a key role in regulating CAR T cells’ longevity and effectiveness.

After decades of limited progress in treating sickle cell disease, we have reached an historical moment with two new gene therapies.

Children’s Hospital of Philadelphia is the lead study site for the development of a gene therapy for multiple sulfatase deficiency.

Learn about a novel disorder caused by rare genetic variants, the importance of global neonatal outcomes, and more, in this week’s edition of In the News.

This month’s Featured Research Trainee for Asian American and Pacific Islander Heritage Month is Huijie (Jade) Feng, PhD

The Master of Regulatory Affairs program is accepting applications for the Fall 2023 academic year.

Cassie Kline, MD, MAS, and Jessica Foster, MD, received a seed grant to study CAR T-cell and radiotherapy for diffuse midline gliomas.

Two scientists with unique skill sets are developing an alternative method for gene therapy delivery with support from a CGTC Seed Grant.

In this Q&A, Drs. Teachey and Diorio discuss their partnership and research of a novel CAR T-cell therapy for one of the most common pediatric cancers.

In this Q&A, hematologist Dr. Kwiatkowski discusses the Food and Drug Administration approval of beti-cel (Zynteglo®), a gene therapy for beta thalassemia.

Next-generation DNA sequencing can predict relapse of patients with acute lymphoblastic leukemia treated with (CAR) T-cell therapy.

CHOP researchers have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth.

The peptide-centric CAR T cells, or PC-CARS, target cancer drivers in tumor cells previously thought unreachable.

CHOP researchers presented preliminary data that CRISPR therapy for inherited blood disorders is safe and effective.